TABLE 1.

Baseline characteristics (n = 200)^a

Parameter	Value
Mean age (yrs) ± SD	59 ± 17
No. (%) of male patients	119 (60)
No. (%) of Caucasian patients	198 (99)
Wt (kg) ± SD	95 ± 25
Mean body mass index (kg/m2) ± SD	33 ± 8
No. (%) of patients with body mass index (kg/m2) of:
25–29.9	96 (48)
30–39.9	77 (39)
40–49.9	18 (9)
≥50	9 (4.5)
Mean Du Dubois body surface area (m2) ± SD	2.0 ± 0.3
No. (%) of patients in intensive care unit at initiation	121 (61)
Mean Charlson comorbidity index ± SD	5.4 ± 3.8
No. (%) of patients on systemic corticosteroids	34 (17)
No. (%) of patients with elevated CRP concentration	48 (24)
No. (%) of patients with low thyroxine concentration	1 (0.005)
No. (%) of patients with elevated thyroxine concentration	1 (0.005)
No. (%) of patients with cancer	68 (34)
Metastatic solid tumor	30 (15)
Renal parameters
Median serum creatinine concentration (mg/dl) (interquartile range)	0.9 (0.6, 1.1)
Mean cystatin C concentration (mg/liter) ± SD	1.3 ± 0.5
Mean eGFR (ml/min) ± SD
Cockcroft-Gaultb	108 ± 64
CKD-EPISCr	102 ± 38
CKD-EPIcysC	78 ± 36
CKD-EPISCr-cysC	89 ± 36
Vancomycin
No. (%) of patients with loading dose	99 (50)
Mean maintenance dose ± SD
Non-wt based (mg)	1,347 ± 304
Wt based (actual) (mg/kg)	15 ± 2.8
Wt based (adjusted) (mg/kg)	18 ± 3.4
Wt based (ideal) (mg/kg)	22 ± 6.8
No. (%) of patients with dosing interval of:
8 h	25 (13)
12 h	139 (70)
24 h	36 (18)
Mean observed trough level (mg/liter) ± SD	15 ± 6.2
No. (%) of patients with observed trough level (mg/liter) of:
<10	40 (20)
10–14.9	65 (32.5)
15–19.9	59 (29.5)
≥20	36 (18)
No. (%) of patients with trough level timing
Before dose 4	142 (71)
Before dose 5 or later	58 (29)

^aAbbreviations: CKD-EPI eGFR, Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate; cysC, cystatin C; SCr, serum creatinine.

^bUsing adjusted body weight.